PN-477

PN-477 is an experimental obesity peptide discussed as a possible retatrutide competitor, especially because an oral version is being developed. People hope for weight loss and easier treatment, but the inspected discussions contain anticipation rather than personal PN-477 results.

Three hormone targets. Protagonist designed it to activate GLP-1, GIP and glucagon receptors: signals involved in appetite, blood sugar and energy use. This is the intended mechanism, not evidence that users lose weight or keep their muscle. Protagonist Therapeutics Form 10-K, year ended December 31, 2025 (Official context · Accessed 2026-09-30)

Oral PN-477o; injected PN-477sc. The company plans once-daily oral dosing and once-weekly injections under the skin. These development plans do not make PN-477 interchangeable with retatrutide. Protagonist Therapeutics Form 10-Q, quarter ended June 30, 2026 (Official context · Accessed 2026-09-30)

Source context — Protagonist Therapeutics Form 10-K, year ended December 31, 2025: Sponsor-authored rationale; mechanism goals cannot establish human efficacy or muscle preservation. Earlier trial forecasts superseded by Q2 filing. Not used in five community practical sections.

Source context — Protagonist Therapeutics Form 10-Q, quarter ended June 30, 2026: Commercial sponsor's design goals and program status; not human effectiveness, tolerability or numerical dosing evidence. Annual and quarterly statements are grouped conservatively with the same sponsor family.

More choice alongside retatrutide. The GLP1Australia thread welcomes another contender mainly because the author wants competition. That is enthusiasm for future options, not a report of appetite suppression, fat loss or better treatment access after using PN-477. A new contender emerges (Community discussion · Accessed 2026-09-30)

Pill convenience has a condition: comparable results and tolerability. A LinkedIn reply puts weight-loss effectiveness and side effects ahead of route convenience. The oral option becomes attractive to that commenter if those outcomes match injections. Neither commenter reports taking PN-477. Archie Reaney: Is Protagonist Therapeutics' Triple-G Pill the Next Game-Changer? (Community opinion · Accessed 2026-09-30)

No dependable PN-477 experience picture yet. The available community record does not establish quieter food thoughts, more energy, nausea or no change after personal exposure. Retatrutide's week-by-week experiences cannot answer that question for PN-477. Positive, unchanged and adverse PN-477 accounts were not located in the inspected discussions.

Animal results are not human benefits. Sponsor-reported mouse weight loss and multi-species oral exposure do not demonstrate better stomach tolerability or muscle preservation in humans. Protagonist Form 10-K: PN-477 preclinical claims (Animal context · Accessed 2026-09-30)

Source context — A new contender emerges: Small discussion of news, not PN-477 exposure. Opening claim about moving to trials predates sponsor-confirmed Phase 1 initiation and is not adopted. Retatrutide maintenance and tirzepatide inflammation comments remain attributed to those compounds. No consensus, prevalence or price claim.

Source context — Archie Reaney: Is Protagonist Therapeutics' Triple-G Pill the Next Game-Changer?: Professional anticipation, not use experience. Sponsor-derived daily/weekly language is identified as design intent. Exact publication date not shown; original record places the post in 2025. No inference from reaction counts.

Source context — Protagonist Form 10-K: PN-477 preclinical claims: Sponsor summary of animal work, not an independently inspected full animal-study report or human comparison. No animal amounts, half-life, onset or duration promoted into community practical answers.

No PN-477 human milligram amount in these community reports. The circulating daily-oral versus weekly-injection description repeats company plans. It does not supply a per-tablet amount, injection amount or daily total from a PN-477 user. Archie Reaney: Is Protagonist Therapeutics' Triple-G Pill the Next Game-Changer? (Community opinion · Accessed 2026-09-30)

Retatrutide's 2, 4, 8 and 12 mg ladder is not a PN-477 range. The original discussion specifically warns against transferring that ladder or orforglipron's oral milligrams. These comparisons do not establish PN-477 dosing.

Source context — Archie Reaney: Is Protagonist Therapeutics' Triple-G Pill the Next Game-Changer?: Professional anticipation, not use experience. Sponsor-derived daily/weekly language is identified as design intent. Exact publication date not shown; original record places the post in 2025. No inference from reaction counts.

No PN-477-specific onset reported here. There is no exposed-user timeline for appetite or other felt changes in these sources. A clinical trial's start date says when development advances, not when someone feels an effect.

No single-dose or after-stopping duration established. No PN-477 diary in the inspected material shows how long appetite changes last or when symptoms return. Daily and weekly administration language describes frequency, not a measured benefit window.

No PN-477 human half-life established in the community record. Half-life is the time for the measured amount to fall by half. The roughly six-day figure borrowed from retatrutide is not a PN-477 measurement. A weekly injection plan also cannot establish that value.

No established community course, break or repeat schedule. The discussion offers no PN-477 titration history or time-off pattern. Maintenance hopes and regain concerns borrowed from other incretins remain comparisons; they do not establish a PN-477 cycle or what happens after stopping.

Comparison names are not a stack. Retatrutide, orforglipron, amycretin and maridebart cafraglutide appear in next-generation weight-loss comparisons. That grouping does not document combined PN-477 use or a reason to combine two triple agonists.

Combination evidence: The inspected discussions contain no combined PN-477 use. [community]

Stomach and heart-rate talk comes from other incretins. Those cautions appear in PN-477 comparisons, but they are not measured PN-477 side-effect rates. No exposed-user record here establishes interaction risks, combination benefits or safety during long-term use.

A vial bearing the name does not verify the compound. Community concern about a future powder listing is an identity warning, not proof that a particular listing exists. A label cannot establish correspondence with the trial formulation or supply a preparation method.

The extra amylin claim remains a rumor. An unlinked social report claims amylin activity. The sponsor identifies PN-477 as triple-G, while listing separate amylin programs. That does not support adding a fourth target to PN-477. Protagonist Therapeutics Form 10-Q, quarter ended June 30, 2026 (Official context · Accessed 2026-09-30)

Pregnancy and breastfeeding were excluded. The trial screens adults for single-dose testing, not long-term safety or outcomes in those groups. ISRCTN12731732: single-dose subcutaneous PN-477 study (Official context · Accessed 2026-09-30)

Source context — Protagonist Therapeutics Form 10-Q, quarter ended June 30, 2026: Commercial sponsor's design goals and program status; not human effectiveness, tolerability or numerical dosing evidence. Annual and quarterly statements are grouped conservatively with the same sponsor family.

Source context — ISRCTN12731732: single-dose subcutaneous PN-477 study: Sponsor-funded trial registry, not published results. The current PDF shows recruiting; an older search extract said not yet recruiting, so no recruitment claim is used publicly. No numerical dose amount listed. Single-dose follow-up through day 57 is not felt duration or a cycle.